Industrializing vaccine stabilization technology

我们的实验室最近发现了一种简单的方法来稳定疫苗，通过将它们储存为由糖聚合物制成的薄膜，这样它们就可以在不需要冷藏的情况下储存。相比之下，如今的疫苗不稳定，需要在持续冷藏条件下储存和运输--这是一个非常复杂的物流问题，通常被称为“冷链”。我们的突破吸引了媒体、投资者和疫苗制造商的关注。我们都看到了巨大的可能性，可以改变所有疫苗在全球的分配方式，无论是在发达国家还是在发展中国家的最偏远地区-一个适用于所有人的单一解决方案。维持冷链占疫苗接种总成本的很大一部分。由于世界偏远地区冷链能力有限，在最需要预防传染病蔓延的地方接种疫苗的机会较少。这些偏远地区的电网通常不可靠（或根本不存在），这限制了向世界上最脆弱的儿童提供疫苗的能力，因为这些疫苗可能长时间暴露在高温下，导致加速热降解。实现这一愿景的下一步是证明其对商业疫苗的适用性，并为大规模生产做好准备。为了实现这一目标，本提案的三个主要目标是：（1）使该技术适用于商业化疫苗，我们将使用三种主要疫苗来证明这一点（MMR、Prevnar® 13和流感疫苗）;（2）表明该技术能够产生不同形式的疫苗-如薄膜，丸剂，粉末，颗粒，粉末和涂层-这将为大规模疫苗生产商创造新产品提供灵活性;以及（3）我们将与世界领先的疫苗制造商不断对话，以确保最大的影响，可能

Our laboratory has recently identified a simple method to stabilize vaccines by storing them as films made of sugar-polymers, so that they can be stored without the need for refrigeration. By contrast, today's vaccines are unstable and need to be stored and transported in constant refrigeration - a very complex logistical problem commonly referred to as the "cold chain". Our breakthrough has attracted the attention of the media, investors and the vaccine manufacturers. We all see immense possibility to change how all vaccines are distributed globally, both in the developed world and the most remote areas of the developing world - a single solution for all. Maintaining a cold chain accounts for a substantial portion of the overall cost of vaccination. Limitedcapacity of the cold chain in remote areas of the world makes vaccination less accessible where it is needed the most to prevent epidemic spreading of infectious diseases. These remote areas typically have unreliable (or non-existent) power grids - this limits the ability to deliver vaccines to the most vulnerable children in the world, as these vaccines can be exposed to elevated temperatures for protracted periods of time leading toaccelerated thermal degradation.The next step toward fulfilling this vision is to demonstrate its applicability to commercial vaccines and prepare for large scale manufacturing. To fulfill this, the three main goals of the this proposal are (1) adapting the technology to commercially available vaccines and we will use three major vaccines to show this (MMR,Prevnar® 13 and flu vaccines); (2) to show that the technology enables the creating of different forms to present the vaccines - as films, pills, powders, granules, powders and coatings - this will provide large scale vaccine producers the flexibility to create new products; and (3) to develop a strategy and process to bring this technology to the market.We will take these steps in constant dialogue with the world's leading vaccine manufactures to ensure the biggest impact possible.